Header Logo

Connection

Shannon Conley to Retinal Diseases

This is a "connection" page, showing publications Shannon Conley has written about Retinal Diseases.
Connection Strength

1.809
  1. Delineating the Clinical Phenotype of Patients With the c.629C>G, p.Pro210Arg Mutation in Peripherin-2. Invest Ophthalmol Vis Sci. 2022 07 08; 63(8):19.
    View in: PubMed
    Score: 0.774
  2. Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010 Sep; 29(5):376-97.
    View in: PubMed
    Score: 0.333
  3. Prph2 disease mutations lead to structural and functional defects in the RPE. FASEB J. 2022 05; 36(5):e22284.
    View in: PubMed
    Score: 0.191
  4. PRPH2/RDS and ROM-1: Historical context, current views and future considerations. Prog Retin Eye Res. 2016 05; 52:47-63.
    View in: PubMed
    Score: 0.123
  5. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium. Biomaterials. 2013 Sep; 34(29):7158-67.
    View in: PubMed
    Score: 0.103
  6. Overexpression of ROM-1 in the cone-dominant retina. Adv Exp Med Biol. 2012; 723:633-9.
    View in: PubMed
    Score: 0.093
  7. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci. 2011 May 10; 52(6):3051-9.
    View in: PubMed
    Score: 0.089
  8. Focus on molecules: RDS. Exp Eye Res. 2009 Sep; 89(3):278-9.
    View in: PubMed
    Score: 0.077
  9. Expression and role of p53 in the retina. Invest Ophthalmol Vis Sci. 2012 Mar 15; 53(3):1362-71.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.